Propranolol D7 hydrochloride Catalog No.:M15330-2 Followed by Combination Therapy with

Followed by Combination Therapy with Dabrafenib and Trametinib for Metastatic Melanoma

is an important pharmacological target in breast cancer therapy

antioxidant and nothing more

is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer

ClH/c6-3-4(7)1-2-5(8)9

Propranolol D7 hydrochloride Catalog No.:M15330-2 Followed by Combination Therapy withPropranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective adrenergic receptor (AR) antagonist, has high affinity for the 1AR and 2AR with Ki values of 1. 8 nM and 0. 8 nM, respectively. Propranolol hydrochloride inhibits [3H] DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for the study of hypertension, pheochromocytoma, myocardial